Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIIB NYSE:HCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIIBBiogen$189.47+0.9%$185.42$121.05▼$205.97$27.73B0.191.17 million shs1.47 million shsHCAHCA Healthcare$392.39-1.1%$468.01$330.00▼$556.52$88.00B1.181.49 million shs2.36 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIIBBiogen+0.89%-0.99%+1.89%-1.33%+49.40%HCAHCA Healthcare-1.18%-9.38%-16.72%-26.38%+2.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIIBBiogen$189.47+0.9%$185.42$121.05▼$205.97$27.73B0.191.17 million shs1.47 million shsHCAHCA Healthcare$392.39-1.1%$468.01$330.00▼$556.52$88.00B1.181.49 million shs2.36 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIIBBiogen+0.89%-0.99%+1.89%-1.33%+49.40%HCAHCA Healthcare-1.18%-9.38%-16.72%-26.38%+2.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIIBBiogen 2.52Moderate Buy$215.6213.80% UpsideHCAHCA Healthcare 2.63Moderate Buy$515.7731.44% UpsideCurrent Analyst Ratings BreakdownLatest BIIB and HCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026HCAHCA Healthcare JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$535.00 ➝ $490.005/18/2026HCAHCA Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/15/2026BIIBBiogen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$214.00 ➝ $225.005/15/2026BIIBBiogen EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/14/2026BIIBBiogen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026BIIBBiogen OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$275.00 ➝ $300.005/4/2026HCAHCA Healthcare ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$560.00 ➝ $500.005/1/2026BIIBBiogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/1/2026BIIBBiogen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$190.00 ➝ $200.005/1/2026BIIBBiogen Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/30/2026BIIBBiogen Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$200.00 ➝ $206.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIIBBiogen$9.89B2.83$22.83 per share8.30$126.33 per share1.50HCAHCA Healthcare$75.60B1.15$44.74 per share8.77($13.42) per share-29.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIIBBiogen$1.29B$9.3220.3311.441.6613.81%12.83%8.01%7/30/2026 (Estimated)HCAHCA Healthcare$6.78B$29.0813.4911.881.268.89%-295.93%11.21%7/24/2026 (Estimated)Latest BIIB and HCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2026Q1 2026BIIBBiogen$2.95$3.57+$0.62$2.15$2.29 billion$2.48 billion4/24/2026Q1 2026HCAHCA Healthcare$7.19$7.15-$0.04$7.15$19.09 billion$19.11 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBIIBBiogenN/AN/AN/AN/AN/AHCAHCA Healthcare$3.120.80%+30.19%10.73%6 YearsLatest BIIB and HCA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/24/2026HCAHCA Healthcarequarterly$0.780.72%6/16/20266/16/20266/30/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIIBBiogen0.343.062.41HCAHCA HealthcareN/A0.830.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIIBBiogen87.93%HCAHCA Healthcare62.73%Insider OwnershipCompanyInsider OwnershipBIIBBiogen0.25%HCAHCA Healthcare1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIIBBiogen7,500147.64 million147.27 millionOptionableHCAHCA Healthcare320,000221.84 million218.51 millionOptionableBIIB and HCA HeadlinesRecent News About These CompaniesCelebrating National EMS Week 2026 with MountainStar HealthcareMay 21 at 4:38 PM | fox13now.comFHCA Virginia colleagues exceed volunteer goal, aid local communitiesMay 21 at 4:38 PM | aol.comAHCA hospital CEO heads to ScionHealthMay 21 at 4:38 PM | beckershospitalreview.comBHCA Healthcare stock outlook: Is Wall Street bullish or bearish?May 21 at 4:38 PM | msn.comBanque Cantonale Vaudoise Lowers Stock Holdings in HCA Healthcare, Inc. $HCAMay 21 at 3:18 AM | marketbeat.comHCA Florida Lawnwood honors survivors, praises first responders and trauma staffMay 20 at 5:58 PM | msn.comHCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 20 at 3:01 PM | seekingalpha.comHCA observes trauma awarenessMay 20 at 12:57 PM | postandcourier.comPMission Hospital spends more than $10M on employee pay raisesMay 20 at 12:57 PM | msn.comHow HCA, Ascension Saint Thomas and Vanderbilt Health plan to take advantage of Rural Health Transformation Program fundsMay 20 at 12:57 PM | bizjournals.comHCA hospital invests $10M to bump payrollMay 20 at 12:57 PM | beckershospitalreview.comBHCA Healthcare, Inc. $HCA Shares Sold by Resona Asset Management Co. Ltd.May 20 at 5:25 AM | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Invests $5.50 Million in HCA Healthcare, Inc. $HCAMay 20 at 3:55 AM | marketbeat.comHCA Healthcare, Inc. (NYSE:HCA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 20 at 2:35 AM | americanbankingnews.comHCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.May 19 at 10:07 AM | marketbeat.comHCA Healthcare Colleagues Volunteer More Than 41,800 Hours During Annual Days of Service InitiativeMay 19 at 8:30 AM | businesswire.comHCA Healthcare, Inc. $HCA Shares Sold by Maj Invest Holding A SMay 19 at 6:26 AM | marketbeat.comHandelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCAMay 19 at 4:22 AM | marketbeat.comHCA CEO Sam Hazen said he regularly travels to Asheville to visit area leaders. Elected officials say they haven’t met himMay 18, 2026 | msn.comQsemble Capital Management LP Takes Position in HCA Healthcare, Inc. $HCAMay 17, 2026 | marketbeat.comNorthwestern Mutual Wealth Management Co. Acquires 649,058 Shares of HCA Healthcare, Inc. $HCAMay 16, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIIB and HCA Company DescriptionsBiogen NASDAQ:BIIB$189.47 +1.67 (+0.89%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$186.45 -3.02 (-1.59%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.HCA Healthcare NYSE:HCA$392.39 -4.28 (-1.08%) Closing price 05/21/2026 03:59 PM EasternExtended Trading$399.58 +7.18 (+1.83%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
